학술논문

Fludarabine, Arabinosyl Cytosine and Idarubicin (FLAI) for Remission Induction in Poor-Risk Acute Myeloid Leukemia.
Document Type
Article
Source
Leukemia & Lymphoma. Jan2001, Vol. 40 Issue 3/4, p335-343. 9p. 3 Charts, 2 Graphs.
Subject
*ACUTE myeloid leukemia
*COMBINATION drug therapy
*DRUG therapy
*DRUG efficacy
Language
ISSN
1042-8194
Abstract
Documents the effectiveness of combination fludarabine, arabinosyl cytosine and idarubicin (FLAI) regimen in poor-risk acute myeloid leukemia patients. Complete remission rate; Projected 2-year and relapse-free survival; Mean time to hematologic recovery; Mobilization of peripheral blood stem cells.